Stem Cell Therapy

Arm 1 for Stargardt Disease

Fakeeh University Hospital, Dubai, United Arab Emirates

Targeting 19 different conditionsArm 1N/ARecruitingLed by Jeffrey Weiss, MDResearch Sponsored by MD Stem Cells

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.

Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Upchange from pre-procedure to 12 months

Awards & highlights

No Placebo-Only Group

Study Summary

This trial will test whether injecting stem cells derived from a patient's own bone marrow can help treat damage to the retina or optic nerve.

Eligible Conditions

Stargardt Disease
Retinal Disease
Blindness
Optic Atrophy
Low Vision
Optic Neuropathy
Ischemic Optic Neuropathy
Leber Optic Neuropathy
Night Blindness
Partial Vision Loss
Macular Abnormality
Retinal Atrophy
Retinal Disorders
Retinitis Pigmentosa
Age-Related Macular Degeneration
Glaucoma

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Select...

Your condition can benefit from BMSC treatment and the procedure poses little risk to your health.

Select...

You have a good chance of benefiting from the BMSC treatment and there is very little risk of harm from the procedure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from pre-procedure to 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from pre-procedure to 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from pre-procedure to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Visual Acuity

Secondary outcome measures

Optical Coherence Tomography (OCT)

Visual Fields

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Arm 1Experimental Treatment1 Intervention

BMSC provided retrobulbar, subtenon and intravenous for one or both eyes

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Arm 1

2006

N/A

~1170

0 / 2Eligibility criteria met

Find a site

Who is running the clinical trial?

MD Stem CellsLead Sponsor

4 Previous Clinical Trials

940 Total Patients Enrolled

Steven Levy, MDStudy Chair

MD Stem Cells

4 Previous Clinical Trials

940 Total Patients Enrolled

Jeffrey Weiss, MDPrincipal Investigator

Coral Springs

4 Previous Clinical Trials

940 Total Patients Enrolled

Media Library

Arm 1 (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03011541 — N/A

Stargardt Disease Research Study Groups: Arm 1

Stargardt Disease Clinical Trial 2023: Arm 1 Highlights & Side Effects. Trial Name: NCT03011541 — N/A

Arm 1 (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03011541 — N/A

Stargardt Disease Patient Testimony for trial: Trial Name: NCT03011541 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this examination currently enrolling participants?

"Per the clinicaltrials.gov listing, recruitment is still open for this experiment that was initially posted on January 1st 2016 and revised lastly in November 25th 2022."

Answered by AI

To what extent is participation in this medical experiment limited?

"Affirmative. According to the information published on clinicaltrials.gov, this medical trial is currently recruiting participants and was initially posted on New Year's Day 2016 before being updated in November 2022. The research team are hoping to enrol 500 patients from two different sites."

Answered by AI